SignalChem Biotech Inc. launches COVID-19 elisa kits for diagnostic research

SignalChem, a global leader in cell signaling and protein engineering, has been conducting research on new coronaviruses since the outbreak of the virus.

SARS-CoV-2 Virus

Image Credit: Kateryna Kon/Shutterstock.com

We understand the importance of accurate and affordable diagnostic solutions and have developed important research tools to help IVD companies work on developing accurate diagnostic tests to detect the SARS-CoV-2,”

Jun Yan, President of SignalChem

The brand new SignalChem's COVID-19 ELISA kits are important research and detection tools to study the novel SARS-CoV-2 and its molecular interactions with the host cell.

Our high-quality ELISA kits can be used for the detection and quantification of SARS-CoV-2 spike protein (RBD) and human anti-SARS-CoV-2 spike protein IgG antibody in biological and recombinant samples.

2019-nCoV S1 Protein Detection ELISA Kit

Catalog No. C19SD-876

SignalChem’s 2019-nCoV (SARS-CoV-2) S1 Protein ELISA Kit is a sandwich enzyme-linked immunosorbent assay to detect and quantify SARS-CoV-2 spike protein in biological and/or recombinant samples.

This high throughput assay is designed based on the principle of using the immobilized ACE2 protein on the surface of 96-well plates to trap the SARS-CoV-2 spike protein present in biological and/or recombinant samples, followed by the addition of horseradish peroxidase (HRP) labeled detection antibody to generate a colorimetric signal.

The intensity of the signal generated is proportional to the amount of SARS-CoV-2 spike protein and allows absolute quantification of the SARS-CoV-2 spike protein present in biological or recombinant samples. SignalChem’s SARS-CoV-2 Spike Protein Detection ELISA Kit is easy to use and has been validated by both internal and external quality protocols.

2019-nCoV S1 Human IgG Detection ELISA Kit

Catalog No. C19S1-877

SignalChem’s 2019-nCoV (SARS-CoV-2) S1 Human IgG ELISA Kit is an immunological screening tool to detect the presence of anti-SARS-CoV-2 IgG in biological and/or recombinant samples.

The indirect ELISA method is designed based on the principle of using a SARS-CoV-2 recombinant spike protein precoated 96-well plate to trap anti-SARS-CoV-2 IgG antibodies produced by the immune system against the viral protein.

Once this complex is formed, another horseradish peroxidase (HRP) labeled antibody specific to the human IgG is added, and the successful binding would generate a colorimetric signal.

The intensity of the color is directly proportional to the amount of target IgG generated by the immune response to the SARS-CoV-2 infection.

About SignalChem Biotech Inc.

SignalChem Biotech Inc. is a Canadian company focused on the research, development, and production of innovative and high-quality human recombinant cell signaling products.

SignalChem strives to support scientists in academia, pharma, and biotech companies around the world by creating effective research tools to advance the basic research in life sciences and to facilitate the efforts in drug discovery and development.

For more information or a quote, please email SignalChem at [email protected] or visit our website at https://signalchem.com/product_elisa_kits.php.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    SignalChem Biotech Inc.. (2020, May 28). SignalChem Biotech Inc. launches COVID-19 elisa kits for diagnostic research. News-Medical. Retrieved on October 19, 2020 from https://www.news-medical.net/news/20200528/SignalChem-Biotech-Inc-launches-COVID-19-elisa-kits-for-diagnostic-research.aspx.

  • MLA

    SignalChem Biotech Inc.. "SignalChem Biotech Inc. launches COVID-19 elisa kits for diagnostic research". News-Medical. 19 October 2020. <https://www.news-medical.net/news/20200528/SignalChem-Biotech-Inc-launches-COVID-19-elisa-kits-for-diagnostic-research.aspx>.

  • Chicago

    SignalChem Biotech Inc.. "SignalChem Biotech Inc. launches COVID-19 elisa kits for diagnostic research". News-Medical. https://www.news-medical.net/news/20200528/SignalChem-Biotech-Inc-launches-COVID-19-elisa-kits-for-diagnostic-research.aspx. (accessed October 19, 2020).

  • Harvard

    SignalChem Biotech Inc.. 2020. SignalChem Biotech Inc. launches COVID-19 elisa kits for diagnostic research. News-Medical, viewed 19 October 2020, https://www.news-medical.net/news/20200528/SignalChem-Biotech-Inc-launches-COVID-19-elisa-kits-for-diagnostic-research.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.